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Abstract
Helicobacter pyloriinfects about 50%oftheworld’spopulationand inevitablyresults inthedevelopment
of gastritis. Of those infected, about 10% develop peptic ulcer disease and roughly 1% develop gastric
cancer. Conversely, some take the view that H. pylori infection provides some protection against
gastro-esophageal reflux disease and possibly asthma. This review aims to explore the case for and
against eradication of the bacterium using a “test and treat” approach amongst the general population.
Introduction
Helicobacter pylori infects about 50% of the world’s
population. It is generally agreed that infection by this
organism inevitably results in the development of
gastritis. Of those infected, about 10% develop peptic
ulcer disease, roughly 1% develop gastric cancer and less
than 0.1% MALT (mucosa-associated lymphoid tissue)
lymphoma [1-3] (Figure 1). These findings indicate that
the organism should be eradicated, especially if the
treatment regimen is highly effective and safe. This
approach, namely "test and treat", has not been met with
universal acceptance, and based on the NIH Consensus
Conference, only symptomatic patients are to be treated
leaving many infected individuals untreated. This is
because the pathogenicity of this organism is regarded by
some as equivocal and thus the issue as to whether
eradication is indicated remains controversial. In this
review, we aim to provide both sides of the debate to
better inform the practicing physician and patient as to
whether eradication would be the best approach.
The controversy centers around whether to eliminate the
organism in all infected individuals or only in sympto-
matic patients on the grounds that the organism may be a
commensal and provide benefits to the asymptomatic
infected person. “Treaters” would suggest that eradication
of the organism would likely reduce the development of
gastric inflammation, development of peptic ulcer disease
(especially in those patients who are also taking non-
steroidal anti-inflammatory drugs [NSAIDs]), and the
theoretical benefit of reducing the progression to frank
gastric malignancy. “Commensalists” suggest that H. pylori,
rather than being a pathogen, is in fact a commensal, and
eradication worsens gastro-esophageal reflux disease or
even induces asthma. This is predicated on relatively few
studies with the underlying concept that gastric atrophy
generated by active infection, or perhaps ammonia genera-
tion by the organism, reduces gastric acidity and hence
protects against gastro-esophageal reflux disease [4]. How-
ever, while clear that the inhabitants of the lower gut do not
cause inflammation and hence can be regarded as
commensals, in the case of H. pylori there is inevitable
gastritis and a robust immune response, not characteristics
of symbionts. The grave consequences of chronic infection
argue strongly for a more vigorous physician response,
whether in symptomatic or non-symptomatic individuals.
H. pylori and gastro-esophageal reflux disease
A recent review evaluated the results of 11 studies and
concluded that H. pylori eradication did not result in a
significant difference in the frequency of symptomatic or
endoscopically proven erosive gastro-esophageal reflux
disease, when compared with persistent infection,
regardless of follow-up period, location, or the baseline
disease [5]. Another in depth review of the literature
agreed with these conclusions, except that in patients
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In contrast to this analysis, an argument has been put
forward for the beneficial effects of H. pylori infection
[7,8]. In particular, a recent analysis was interpreted to
show that infection with H. pylori reduced the onset of
Barrett’s esophagus, which is generally regarded as a step
on the way to cancer of the esophagus. However, while
the correlation between infection and gastritis and
intestinal metaplasia was very strong, there was a weak
correlation between esophageal intestinal metaplasia
and infection [9]. This remains a controversial area [10].
A recent review of the literature concluded that there is
no significant difference in the incidence of H. pylori
infection between patients with Barrett’s esophagus and
controls [11].
There have also been multiple studies on the association
between gastro-esophageal reflux disease and esophageal
adenocarcinoma, and the consensus is that acid reflux
predisposes the squamous epithelium of the esophagus
to development of columnar metaplasia [10]. However,
as discussed above, there is no consensus as to the role of
infection in protection against gastro-esophageal reflux
disease. Given the mixed results, more studies are needed
in this area, but, to date, evidence for the objection that
has been made to the eradication of H. pylori, either on
the grounds that it ameliorates reflux disease or
esophageal intestinal metaplasia, is rather weak. Given
the possible explanations for the lower rates of gastro-
esophageal reflux disease and Barrett’s esophagus seen
in H. pylori infections, in some studies other treatments
could compensate for this were the infection removed,
so this is not an argument against eradication. For
example, there are many ways of treating acid reflux,
which would obviate the possible consequences of
eradication.
Therearealsoveryfewprospectivestudiesontheassociation
between infection by H. pylori and gastro-esophageal reflux
disease or Barrett’s esophagus. A recent community-based
study showed that there was indeed an inverse association
between H. pylori antibody status and gastro-esophageal
reflux disease diagnosis in 611 patients [12], suggesting that
a portion of the risk of gastro-esophageal reflux disease may
be higher in the absence of infection. A similar set of
conclusions was drawn from a study investigating the
incidence of new diagnosis of Barrett’s esophagus and
gastro-esophageal reflux disease, in patients infected with H.
pylori (particularly with patients with CagA+ strains) versus
uninfected controls [13]. The percentage of infection was
11.7inBarrett’sesophaguspatients,9.6ingastro-esophageal
reflux disease patients and 22.7 in healthy control subjects
with a total of 929 subjects. There are various possible
explanations for this observation. For example, infected
patients may have suppressed acid secretion and had gastric
atrophy. Alternatively, they may have increased gastric
emptying and hence decreased acid reflux or increased
appetite due to increased ghrelin (a hormone that regulates
appetite) and consequent weight gain. A third possibility is
that theammoniagenerated bythe organism could partially
neutralize gastric acid. Whether ornot infection is associated
with decreased acid reflux, clearly gastro-esophageal reflux
disease should be treated so that symptoms disappear. This
is certainly less challenging than treating gastric cancer.
There have also been multiple studies on the association
between gastro-esophageal reflux disease and esophageal
adenocarcinoma, and the consensus clearly is that acid
reflux predisposes the squamous epithelium of the
esophagus to development of columnar metaplasia
[10]. However, as discussed above, there is no consensus
as to the role of infection in protection against gastro-
esophageal reflux disease.
H. pylori and gastric cancer
It is now well accepted that habitation of the body of the
stomach by H. pylori results in a large increase in the
incidence of gastric adenocarcinoma [14-16]. Although
the mechanism of neoplastic transformation remains an
area of active investigation, the induction of neoplasia by
Figure 1. Consequences of H. pylori infection
An outline of the gastric disorders resulting from infection by H. pylori
showing the high incidence of gastritis followed by peptic ulcer diseases
(duodenal or gastric ulcer), gastric atrophy gastric cancer and MALT
lymphoma. Evidently, eradication of the organism would prevent these
effects. Other systemic disorders have also been linked to infection.
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a type I carcinogen by WHO.
The interaction between H. pylori and the gastric epithe-
lium involves many factors. The major barrier that the
organism must overcome in the stomach is the acidity of
the gastric surface, which is greater in the fundus than the
antrum. The antrum is the most frequent site of infection
suggestingthatthepHatthesurfaceofantralglandsiswell
tolerated by H. pylori allowing both survival and growth.
Withprotonpumpinhibitoradministration,theorganism
is found largely in the fundus, suggesting that the increase
ofintragastric pHinduced byinhibitionofthe gastricH,K
ATPase favors colonization of the fundus rather than the
antrum [17].
The first consequence of H. pylori infection is gastritis,
which may bethe direct result ofammonia secreted bythe
bacteriaorproductsofthecagpathogenicityisland(oneof
the majorpathogenicitydeterminantsinH.pylori),suchas
the virulence factor cagA (mediated by a type IV secretion
system)[18].AnothertoxicvirulencefactorisvacA,which,
after proteolysis, is able to insert into the membrane of
host cells and after penetration induce vacuolization [19].
Perhaps a major contribution to carcinogenicity is the
inductionof a local immune response,andin vitromodels
have shown that H. pylori is able to induce cytokine
production [20]. On immune cells themselves, toll-like
receptors 2 and 4 that recognize lipopolysaccharide (LPS)
mediate the innate immune response to infection [21].
The burden of H. pylori infection for gastric cancer is
illustrated in a Japanese study of about 1,500 sympto-
matic patients. About 3% of those infected by H. pylori
had developed gastric cancer, while none of the unin-
fected group did so. Furthermore, those patients with
duodenal ulcer did not show a propensity to develop
cancer while those with gastric ulcer or non-ulcer
dyspepsia did [22]. This indicates that infection of the
body of the stomach results in a more serious conse-
quence than infection of the antrum (the portion of the
stomach nearest the duodenum) or duodenum. This is
particularly relevant in symptomatic patients undergoing
treatment with proton pump inhibitors, in whom the
organism has a tendency to leave the antrum and inhabit
the fundus. Fundic infection predisposes to intestinal
metaplasia and eventually adenocarcinoma, so patients
placedonchronic proton pumpinhibitor therapyshould
be checked for active infection and if present, every effort
should be made to eradicate the organism.
H. pylori and other diseases
A variety of ailments have been associated with infection,
both positively and negatively affected by eradication
(see [23] for a recent review). Prominent among those
that are worsened by infection are idiopathic thrombo-
cytic purpura, where the platelet count returns to normal
after eradication, and iron deficiency anemia where
eradication improves the efficacy of iron administration.
Various allergic diseases, such as asthma and various
allergies, show a negative association epidemiologically
with H. pylori eradication [24]. It may be that activation
of Th1 cells by H. pylori neutrophil-activating protein,
and reduced activation of Th2, could account for the
beneficial effect on allergic responses [25].
Strategies for eradication of H. pylori
Perhaps if eradication of the infection was straightfor-
ward, a test and treat strategy would be more accepted.
For an infection, where routine treatment is adopted
without testing for susceptibility, a rate of > 90% is
usuallyrequired for satisfactory outcomefor treatment of
infections, but routine, uncritical treatment often pre-
vents recognition that this treatment is not meeting the
requirement for success. In the case of eradication
therapy, there was early recognition that more than one
drug was required and the first generally used regimen
was a combination of bismuth, tetracycline and metro-
nidazole, quickly followed by the addition of a proton
pump inhibitor such as omeprazole. This treatment
required3or4dosesperdayandwasnotwidelyaccepted.
It was later replaced by the now classical triple therapy
requiring twice daily dosing of a proton pump inhibitor,
clarithromycin and amoxicillin or metronidazole. How-
ever, treatment success with this therapy has fallen below
80%, largely due to clarithromycin or metronidazole
resistance [26]. Another issue is compliance in sympto-
matic patients where the proton pump inhibitor ablates
the symptoms and the patient stops taking the medica-
tions. Currently, the state of eradication therapy is in flux
with no one regimen offering the combination of
simplicity and success.
What isnow universal in therapyis the accompaniment of
antibiotics by an inhibitor of acid secretion, now usually a
proton pump inhibitor. This raises the question of the
reasonfortherequirementforacidsecretoryinhibition.H.
pyloriis a slow-growingorganism,evenatneutralpH,with
a division time of 4-6 hours in contrast to 20 minutes for
E. coli. Its growth slows at acidic pH and stops at pH 3.0.
Although there has been controversy as to the pH of its
habitat in the stomach, transcriptomal analysis provides
evidencethatitshabitatisindeedacidic,probablyatabout
a median pH of 3.5. For antibiotics such as tetracycline,
clarithromycin and amoxicillin, growth is essential for
their efficacy. So it is likely that the elevation of pH by
proton pump inhibitors accounts for their synergism with
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achieved by proton pump inhibitors is ~ 4.0, still low
enough for many of the organisms to remain quiescent.
More effective inhibition of acid secretion would likely
improve eradication with a bactericidal drug such as
amoxicillin, to which current resistance is < 1%. This
would result in dual therapy with BID (twice daily)
administration of the inhibitor of acid secretion and
amoxicillin. In Japan, where the incidence of slow proton
pump inhibitor metabolizers is quite high, eradication of
H. pylori was achieved with the proton pump inhibitor
omeprazole and amoxicillin alone rather than triple
therapy [27]. Given this result, it seems unfortunate that
the pharmaceutical industry appears to have abandoned
H. pylori as a desirable therapeutic target.
Another point to be made is that if eradication is
undertaken, there must be quantitative assessment of
successful therapy, with either the stool antigen test or
urea breath test, and this should be a requirement for
eradication treatment.
Conclusions
The controversy over whether H. pylori should be
eradicated in all infected individuals or just in sympto-
matic patients, reflects the risk to benefit ratio. There is
no controversy as to the sequelae of infection: peptic
ulcer disease, gastric cancer and MALT lymphoma. In
contrast, there is disagreement as to effects of eradication
on gastro-esophageal reflux disease or Barrett’s esopha-
gus. In light of this, the weight of evidence argues for
eradication as preventive medicine and, importantly, if
gastro-esophageal reflux disease symptoms are present
these should be treated vigorously.
The therapeutic choices available currently, however,
highlight the problem that eradication may not be easy.
Current therapy is complicated and less than optimal. In
principal, if better acid suppressing agents become
available, then it seems likely that eradication could be
improved and become simpler.
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